Hoth Therapeutics Announces HT-ALZ Therapeutic Shows Cognitive Improvements In Alzheimer’s Disease Mouse Model; Shares Halted On Circuit Breaker
Hoth Therapeutics, Inc. (NASDAQ:HOTH), a patient-focused biopharmaceutical company, today announced proof-of-concept data generated using cognitive and behavioral assessments in an Alzheimer's disease
Abbott’s Deep Brain Stimulation Receives FDA’s Breakthrough Device Tag To Manage Depression
The FDA has granted Breakthrough Device Designation to Abbott Laboratories (NYSE:ABT) deep brain stimulation (DBS) system in treatment-resistant depression (TRD), a form…
‘Delaware Health Officials Report First Probable Case Of Monkeypox’ -CBS Philly
https://philadelphia.cbslocal.com/2022/07/12/delaware-first-monkeypox-case/
Rhythm Shares Climb Following Positive Interim Results From Mid-Stage Obesity Study
Rhythm Pharmaceuticals (NASDAQ: RYTM) announced positive interim results from a Phase 2 clinical trial evaluating setmelanotide for the treatment of severe obesity and hyperphagia in people living with hypothalamic obesity.
Y-mAbs’ Announces Clearance of IND For GD2-SADA
NEW YORK, July 12, 2022 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the "Company" or "Y-mAbs") (NASDAQ:YMAB) a commercial-stage biopharmaceutical company focused on the development and
Abbott Receives FDA’s Breakthrough Device Designation To Explore Use Of Deep Brain Stimulation To Manage Severe Depression
Breakthrough Device Designations are given by the U.S. FDA to expedite the review of technologies that can improve the lives of people with life-threatening or debilitating conditions
Each year, 2.8 million Americans
Synlogic Initiates Phase 1 Study of SYNB1353 for the Treatment of Homocystinuria
Expected data in H2 2022 brings Synlogic to three clinical readouts this year
Third candidate in less than two years to enter the clinic; Reflects productivity of Synthetic Biotic platform
CAMBRIDGE, Mass., July
Verve Therapeutics Doses First Human With An Investigational In Vivo Base Editing Medicine, VERVE-101, As A Potential Treatment For Heterozygous Familial Hypercholesterolemia
Phase 1b Clinical Trial, heart-1, Now Underway and Enrolling Patients with Heterozygous Familial Hypercholesterolemia in New Zealand
Company Executing VERVE-101 Global Regulatory Strategy with Potential